Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at D. Boral Capital

by · The Markets Daily

D. Boral Capital reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA – Free Report) in a research report report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $15.00 target price on the stock.

Several other equities research analysts have also commented on the stock. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Friday, November 14th. Lake Street Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research report on Monday, November 24th. Finally, Wall Street Zen raised shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

View Our Latest Stock Analysis on COYA

Coya Therapeutics Trading Down 1.9%

NASDAQ COYA opened at $5.15 on Monday. The stock has a market capitalization of $107.74 million, a price-to-earnings ratio of -4.64 and a beta of 0.25. The stock has a 50-day moving average of $5.86 and a 200 day moving average of $6.05. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $8.29.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. Equities analysts predict that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new position in Coya Therapeutics in the 3rd quarter worth approximately $28,000. Lantern Wealth Advisors LLC acquired a new stake in shares of Coya Therapeutics in the third quarter valued at approximately $66,000. Prosperity Wealth Management Inc. lifted its position in Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after buying an additional 3,350 shares in the last quarter. Citadel Advisors LLC lifted its position in Coya Therapeutics by 51.3% during the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after buying an additional 22,120 shares in the last quarter. Finally, Dauntless Investment Group LLC boosted its stake in Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after buying an additional 101,932 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

Featured Articles